Goetz CG - Search Results

1

MDS research criteria for prodromal Parkinson's disease.

Berg D, Postuma RB, Adler CH, Bloem BR, Chan P, Dubois B, Gasser T, Goetz CG, Halliday G, Joseph L, Lang AE, Liepelt-Scarfone I, Litvan I, Marek K, Obeso J, Oertel W, Olanow CW, Poewe W, Stern M, Deuschl G. Berg D, et al. Among authors: goetz cg. Mov Disord. 2015 Oct;30(12):1600-11. doi: 10.1002/mds.26431. Mov Disord. 2015. PMID: 26474317 Review.

2

Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group.

Jankovic J, McDermott M, Carter J, Gauthier S, Goetz C, Golbe L, Huber S, Koller W, Olanow C, Shoulson I, et al. Jankovic J, et al. Neurology. 1990 Oct;40(10):1529-34. doi: 10.1212/wnl.40.10.1529. Neurology. 1990. PMID: 2215943

3

Levodopa in the treatment of Parkinson's disease: a consensus meeting.

Agid Y, Ahlskog E, Albanese A, Calne D, Chase T, De Yebenes J, Factor S, Fahn S, Gershanik O, Goetz C, Koller W, Kurth M, Lang A, Lees A, Lewitt P, Marsden D, Melamed E, Michel PP, Mizuno Y, Obeso J, Oertel W, Olanow W, Poewe W, Pollak P, Tolosa E, et al. Agid Y, et al. Mov Disord. 1999 Nov;14(6):911-3. doi: 10.1002/1531-8257(199911)14:6<911::aid-mds1001>3.0.co;2-h. Mov Disord. 1999. PMID: 10584663 Review. No abstract available.

4

A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease.

Olanow CW, Goetz CG, Kordower JH, Stoessl AJ, Sossi V, Brin MF, Shannon KM, Nauert GM, Perl DP, Godbold J, Freeman TB. Olanow CW, et al. Among authors: goetz cg. Ann Neurol. 2003 Sep;54(3):403-14. doi: 10.1002/ana.10720. Ann Neurol. 2003. PMID: 12953276 Clinical Trial.

5

Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study).

Olanow CW, Damier P, Goetz CG, Mueller T, Nutt J, Rascol O, Serbanescu A, Deckers F, Russ H. Olanow CW, et al. Among authors: goetz cg. Clin Neuropharmacol. 2004 Mar-Apr;27(2):58-62. doi: 10.1097/00002826-200403000-00003. Clin Neuropharmacol. 2004. PMID: 15252265 Clinical Trial. No abstract available.

6

Goetz CG, Wuu J, Curgian L, Leurgans S. Goetz CG, et al. Mov Disord. 2006 Feb;21(2):267-70. doi: 10.1002/mds.20701. Mov Disord. 2006. PMID: 16161144

7

Does seasonal variation affect hallucinations in PD? A longitudinal study.

Goetz CG, Li JM, Wuu J, Leurgans S. Goetz CG, et al. Mov Disord. 2006 Jun;21(6):863-5. doi: 10.1002/mds.20840. Mov Disord. 2006. PMID: 16538649

8

Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease.

Friedman JH, Berman RM, Goetz CG, Factor SA, Ondo WG, Wojcieszek J, Carson WH, Marcus RN. Friedman JH, et al. Among authors: goetz cg. Mov Disord. 2006 Dec;21(12):2078-81. doi: 10.1002/mds.21091. Mov Disord. 2006. PMID: 17013906

9

Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial.

Goetz CG, Damier P, Hicking C, Laska E, Müller T, Olanow CW, Rascol O, Russ H. Goetz CG, et al. Mov Disord. 2007 Jan 15;22(2):179-86. doi: 10.1002/mds.21226. Mov Disord. 2007. PMID: 17094088 Clinical Trial.

10

Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan.

Goetz CG, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stebbins GT, Stern MB, Tilley BC, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, Van Hilten JJ, LaPelle N. Goetz CG, et al. Mov Disord. 2007 Jan;22(1):41-7. doi: 10.1002/mds.21198. Mov Disord. 2007. PMID: 17115387

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

559 results

Search Page